TRVN:OTCMKTS
Trevena Inc
0,066 $
0,00%
(0,00) 1D
12. okt., 14:57:26 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za TRVN …
Tržna kapitalizacija
57,01 tis.
Povprečni promet
210,00
Promet
16,00
52-tedenski najvišji tečaj
1,50 $
52-tedenski najnižji tečaj
0,00 $
Beta
1,07
Št. izdanih delnic
864,00 tis.
Št. zaposlenih
23
Tržna kapitalizacija
57,01 tis.
Povprečni promet
210,00
Promet
16,00
52-tedenski najvišji tečaj
1,50 $
52-tedenski najnižji tečaj
0,00 $
Beta
1,07
Št. izdanih delnic
864,00 tis.
Št. zaposlenih
23
Novice
Iz spletnih virov in novičarskih partnerjev
ad-hoc-news.de
·
pred 21 urami
MarketBeat estimates results for Trevena stock
Profil
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Vizitka: Trevena Inc
Generalni direktor-
Št. zaposlenih23
Ustanovljeno2007
SedežAtlanta, Georgia, Združene države Amerike
Sektor-
Spletno mestotrevena.com